These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 38815167

  • 1. Synthesis and Biological Evaluation of Methoxypolyethylene-Glycol-Substituted Abiraterone Derivatives as Potential Antiprostate Cancer Agents.
    Meng S, Zhu N, Han D, Li B, Zhang X, Zhang J, Liu T.
    Mol Pharm; 2024 Jul 01; 21(7):3186-3203. PubMed ID: 38815167
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hedgehog Proteins Consume Steroidal CYP17A1 Antagonists: Potential Therapeutic Significance in Advanced Prostate Cancer.
    Bordeau BM, Ciulla DA, Callahan BP.
    ChemMedChem; 2016 Sep 20; 11(18):1983-6. PubMed ID: 27435344
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.
    Bruno RD, Vasaitis TS, Gediya LK, Purushottamachar P, Godbole AM, Ates-Alagoz Z, Brodie AM, Njar VC.
    Steroids; 2011 Nov 20; 76(12):1268-79. PubMed ID: 21729712
    [Abstract] [Full Text] [Related]

  • 6. Abiraterone in prostate cancer: a new angle to an old problem.
    Stein MN, Goodin S, Dipaola RS.
    Clin Cancer Res; 2012 Apr 01; 18(7):1848-54. PubMed ID: 22451619
    [Abstract] [Full Text] [Related]

  • 7. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
    Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS.
    J Clin Oncol; 2010 Mar 20; 28(9):1489-95. PubMed ID: 20159823
    [Abstract] [Full Text] [Related]

  • 8. New benzothieno[2,3-c]pyridines as non-steroidal CYP17 inhibitors: design, synthesis, anticancer screening, apoptosis induction, and in silico ADME profile studies.
    Khalil NA, Ahmed EM, Zaher AF, Sobh EA, El-Sebaey SA, El-Zoghbi MS.
    J Enzyme Inhib Med Chem; 2021 Dec 20; 36(1):1839-1859. PubMed ID: 34338119
    [Abstract] [Full Text] [Related]

  • 9. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
    Rafferty SW, Eisner JR, Moore WR, Schotzinger RJ, Hoekstra WJ.
    Bioorg Med Chem Lett; 2014 Jun 01; 24(11):2444-7. PubMed ID: 24775307
    [Abstract] [Full Text] [Related]

  • 10. Dirty deeds done dirt cheap: sensitization of prostate cancer cells to abiraterone treatment using hydroxylated polychlorinated biphenyls.
    Daragan G, Hoffmann J, Vasko T, Mustea A, Burchardt M, Kraus T, Stope MB, Ziegler P.
    Invest New Drugs; 2020 Apr 01; 38(2):541-545. PubMed ID: 31292837
    [Abstract] [Full Text] [Related]

  • 11. N-substituted piperazinopyridylsteroid derivatives as abiraterone analogues inhibit growth and induce pro-apoptosis in human hormone-independent prostate cancer cell lines.
    Brossard D, Zhang Y, Haider SM, Sgobba M, Khalid M, Legay R, Duterque-Coquillaud M, Galera P, Rault S, Dallemagne P, Moslemi S, El Kihel L.
    Chem Biol Drug Des; 2013 Nov 01; 82(5):620-9. PubMed ID: 23906044
    [Abstract] [Full Text] [Related]

  • 12. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
    Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS.
    J Clin Oncol; 2009 Aug 10; 27(23):3742-8. PubMed ID: 19470933
    [Abstract] [Full Text] [Related]

  • 13. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
    Bird IM, Abbott DH.
    J Steroid Biochem Mol Biol; 2016 Oct 10; 163():136-46. PubMed ID: 27154414
    [Abstract] [Full Text] [Related]

  • 14. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
    Pinto-Bazurco Mendieta MA, Negri M, Jagusch C, Müller-Vieira U, Lauterbach T, Hartmann RW.
    J Med Chem; 2008 Aug 28; 51(16):5009-18. PubMed ID: 18672868
    [Abstract] [Full Text] [Related]

  • 15. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
    Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, Oommen NB, Folkerd E, Dowsett M, Arlt W, de Bono JS.
    J Clin Endocrinol Metab; 2012 Feb 28; 97(2):507-16. PubMed ID: 22170708
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
    Yin L, Hu Q.
    Nat Rev Urol; 2014 Jan 28; 11(1):32-42. PubMed ID: 24276076
    [Abstract] [Full Text] [Related]

  • 20. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.
    Stein MN, Patel N, Bershadskiy A, Sokoloff A, Singer EA.
    Asian J Androl; 2014 Jan 28; 16(3):387-400. PubMed ID: 24759590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.